Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,743.65INR
3:44pm IST
Change (% chg)

Rs5.60 (+0.20%)
Prev Close
Rs2,738.05
Open
Rs2,739.80
Day's High
Rs2,761.95
Day's Low
Rs2,715.15
Volume
364,302
Avg. Vol
691,170
52-wk High
Rs2,964.00
52-wk Low
Rs1,872.95

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Launches Bupropion Hydrochloride Extended-Release Tablets In U.S.
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP (SR) IN U.S. MARKET.  Full Article

Dr.Reddy's Issued Form 483 With 8 Observations Post Audit Of Duvvada Formulations Manufacturing Plant
Tuesday, 20 Aug 2019 

Aug 20 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF DUVVADA FORMULATIONS MANUFACTURING PLANT BY USFDA COMPLETED; CO ISSUED FORM 483 WITH 8 OBSERVATIONS.  Full Article

Dr.Reddy's Laboratories Launches Versavo In India
Monday, 19 Aug 2019 

Aug 19 (Reuters) - Dr.Reddy's Laboratories Ltd ::ANNOUNCES LAUNCH OF VERSAVO (BEVACIZUMAB BIOSIMILAR) IN INDIA.  Full Article

Exelixis And Aurigene Enter Into Exclusive Collaboration
Thursday, 1 Aug 2019 

July 31 (Reuters) - Exelixis Inc ::EXELIXIS AND AURIGENE ENTER INTO EXCLUSIVE COLLABORATION, OPTION AND LICENSE AGREEMENT TO DISCOVER AND DEVELOP NOVEL THERAPIES FOR CANCER.EXELIXIS INC - COMPANIES WILL PARTNER TO ADVANCE SMALL MOLECULES IN UP TO SIX DISCRETE PROJECTS.EXELIXIS INC - WILL MAKE AN UPFRONT PAYMENT OF $10 MILLION FOR EXCLUSIVE OPTIONS TO LICENSE THREE PREEXISTING PROGRAMS FROM AURIGENE.EXELIXIS INC - WILL ALSO CONTRIBUTE RESEARCH FUNDING TO AURIGENE TO FACILITATE DISCOVERY AND PRECLINICAL DEVELOPMENT WORK ON ALL SIX PROGRAMS.EXELIXIS INC - AURIGENE RETAINS LIMITED DEVELOPMENT AND COMMERCIAL RIGHTS FOR INDIA AND RUSSIA.  Full Article

Dr.Reddy's Laboratories Says FDA Issued Form 483 With 5 Observations For Hyderabad Plant
Friday, 12 Jul 2019 

July 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS AUDIT AT API MANUFACTURING PLANT 2 AT BOLLARAM, HYDERABAD BY THE US FDA, HAS BEEN COMPLETED.SAYS USFDA ISSUED A FORM 483 WITH 5 OBSERVATIONS FOR HYDERABAD PLANT .  Full Article

Dr.Reddy's Labs Launches Over-the-counter Mucinex D Tablets In U.S.
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES OVER-THECOUNTER STORE BRAND EQUIVALENT OF MUCINEX D EXTENDED RELEASE TABLETS IN THE U.S. MARKET.  Full Article

Dr.Reddy's Laboratories Launches Carboprost Tromethamine Injection USP In U.S.
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES CARBOPROST TROMETHAMINE INJECTION USP, 250 MCG/ML (1ML) SINGLE-DOSE VIAL IN U.S..  Full Article

Dr.Reddy's Launches Tobramycin Inhalation Solution In U.S.
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Dr.Reddy's Laboratories Ltd ::ANNOUNCES THE LAUNCH OF TOBRAMYCIN INHALATION SOLUTION, USP IN THE U.S. MARKET.  Full Article

U.S. Appeals Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
Friday, 26 Apr 2019 

April 26 (Reuters) - Eli Lilly and Co ::U.S. COURT OF APPEALS RULES IN FAVOR OF LILLY IN ALIMTA VITAMIN REGIMEN PATENT LAWSUIT.ELI LILLY AND CO - IF PATENT IS ULTIMATELY UPHELD THROUGH ALL REMAINING CHALLENGES, ALIMTA WOULD MAINTAIN U.S. EXCLUSIVITY UNTIL MAY 2022.ELI LILLY - U.S. COURT OF APPEALS DECISION UPHOLDS AN OCTOBER 2017 DECISION BY PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE.ELI LILLY AND CO - DR. REDDY'S LABORATORIES AND HOSPIRA HAVE APPEALED DISTRICT COURT'S DECISIONS.ELI LILLY AND CO - HEARING ON THOSE APPEALS IS SCHEDULED FOR JUNE 2019..  Full Article

Dr.Reddy's Laboratories Gets Approval For Clopidogrel In China
Thursday, 25 Apr 2019 

April 25 (Reuters) - Dr.Reddy's Laboratories Ltd ::HAS RECEIVED APPROVAL FOR THE PRODUCT CLOPIDOGREL IN CHINA.SAYS SALES FROM ANTI-BLOOD CLOTTING DRUG WILL NOT BE MATERIAL IN FY2020.  Full Article